Supernus Pharma (SUPN) Misses Q2 EPS by 144c

Supernus Pharma (NASDAQ: SUPN) reported Q2 EPS of ($1.01), $1.44 worse than the analyst estimate of $0.43. Revenue for the quarter came in at $219.1 million versus the consensus estimate of $205.63 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Reports Of Blasts Across Iran's Southern Regions: State TV - Bloomberg
• DA Davidson Reiterates Underperform Rating on c3.ai (AI)
• FuelCell Energy (FCEL) call put ratio 1 call to 1 put into quarter results